Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2025 23:59 ET | Source: Global Liver Institute

Global Fatty Liver Day 2025: Elevating Liver Health in the Metabolic Health Conversation

Washington, D.C., June 11, 2025 (GLOBE NEWSWIRE) -- On the second Thursday in June, Global Fatty Liver Day (formerly International NASH Day) spotlights one of the most widespread yet under-addressed...
January 27, 2025 07:45 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer

Kailera Therapeutics today announced the appointment of Jamie Coleman, former U.S. Brand Leader for Zepbound, as Chief Commercial Officer.
December 10, 2024 14:10 ET | Source: Remedy Plan Therapeutics

UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax
December 10, 2024 08:00 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax
October 01, 2024 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions

Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.
April 13, 2023 14:03 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes

Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...
December 15, 2022 04:50 ET | Source: Research and Markets

$2.7 Billion Worldwide Pet Diabetes Care Industry to 2027 - Players Include ACON Laboratories, Allison Medical, i-SENS and Trividia Health

Dublin, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The "Pet Diabetes Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
February 04, 2020 08:30 ET | Source: Crown Bioscience

Yale School of Medicine to Present Data on Reversal of Fatty Liver and Plasma Triglycerides in NHPs

SAN DIEGO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the presentation of new NAFLD/NASH data with Yale School of Medicine. The presentation encompasses preclinical...
March 12, 2019 08:30 ET | Source: Crown Bioscience

Crown Bioscience Inc. and Charles River Laboratories Enter Agreement to Expand Access to ZDSD Rat Model

SAN DIEGO, Calif. and WILMINGTON, Mass., March 12, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance...
November 08, 2018 08:00 ET | Source: Crown Bioscience

Crown Bioscience Expands Cardiovascular & Metabolic Disease Research Capability

The Company Offers New Non-GLP Services & Translational Rodent Models at its expanded site in Louisiana SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug...

Next Page keyboard_arrow_right